Skip to content

NHLBI R61/R33 Early Phase Eligibility Guide

Updated 7 official sources

Quick Answer: NHLBI R61/R33 early phase clinical trial eligibility in 2026 turns on 8 checks: HLBS mission fit, Phase 0/I status, therapeutic or diagnostic product, final-stage readiness, R61 milestones, R33 trial execution, budget caps, and 12-week program contact timing.

Full answer and how we checked it

NHLBI R61/R33 early phase clinical trial eligibility in 2026 turns on 8 checks: HLBS mission fit, Phase 0/I status, therapeutic or diagnostic product, final-stage readiness, R61 milestones, R33 trial execution, budget caps, and 12-week program contact timing.

Who this is for: This guide is for NHLBI investigators, clinical-trial teams, biotech collaborators, device teams, diagnostic developers, and sponsored-research offices checking whether PAR-25-026 is the right phased route before contacting NHLBI.

Data note: This guide uses NIH PAR-25-026 (opens in a new tab), NHLBI clinical trial development continuum (opens in a new tab), NHLBI clinical trial FAQ (opens in a new tab), NIH clinical trials policy (opens in a new tab), Grants.gov listing 357543 (opens in a new tab), and Grantsights award-data signals checked on June 2, 2026.

In this guide

Quick Facts

Agency
HHS
Deadline
Feb 3, 2027
Status
Open

Assistance Listing 93.840: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.840, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
88
Avg Award (whole listing)
$2,201,999
Median Award (whole listing)
$2,225,359
Total Funding (FY2024, whole listing)
$1.2M
YoY Funding Trend
-97.5%

Data last verified: May 19, 2026

According to NIH PAR-25-026 (opens in a new tab), this NOFO supports investigator-initiated Phase 0 and Phase I clinical trials, including bridging studies, for diagnostic and therapeutic interventions for heart, lung, blood, and sleep disorders in adults and children.

The key question is whether the product is ready for a phased path from final start-up work to early human trial execution. It isn't enough to have an exciting intervention. NHLBI says submissions containing animal studies are not permitted for this NOFO.

Use this guide with the live NHLBI early phase R61/R33 program record, NHLBI clinical trial pilot R34 guide, NHLBI Emerging Investigator Award R35 guide, NIH Clinical Center U01 guide, Latin America health disparities R01 guide, NIH grants complete guide, and the Grantsights grant database.

From Manusights, our sister product

Applying for an R01 or R21? Manusights offers an AI critique of your application against NIH's published review criteria: $149 for a new R01 or R21, $199 for a resubmission. Back within 3 business days of your upload.

Order a grant review

Source Check

Checked June 2026; due dates rechecked November 9, 2026.

7 official-source checks should happen before a team treats PAR-25-026 as the right NHLBI route. NIH lists this as an R61/R33 clinical-trial-required route for Phase 0 and Phase I clinical trials, including bridging studies, for diagnostic or therapeutic interventions in heart, lung, blood, and sleep disorders. The June 4, 2026 and October 2, 2026 receipt dates have passed. On October 20, 2026, NHLBI added one more receipt date in NOT-HL-27-002 (opens in a new tab): February 3, 2027, for new applications and for resubmissions or revisions, due by 5 p.m. local time. PAR-25-026 (opens in a new tab) now expires February 4, 2027, so February 3 is the last window under this notice. Check the NHLBI funding opportunities page (opens in a new tab) for a replacement before planning anything later.

NIH also states that the R61 phase can run up to 2 years, the R33 phase can run up to 3 years, and the combined project period can be up to 5 years. R61 budgets are limited to $250,000 in direct costs per year, while R33 budgets should not exceed $1,515,000 in direct costs per year. Submissions containing animal studies are not permitted.

Source checkWhat to verify before writing
Trial phasePhase 0, Phase I, or bridging study, not Phase II or III
Product readinessFinal formulation, stability, shipping, IND/IDE, protocol, and site training are near enough for R61
R33 executionTrial launch, accrual, retention, safety, and dashboard milestones are measurable
BudgetR61 and R33 direct-cost limits are phase-specific
Bad fitAnimal studies, BESH-only work, observational studies, or Phase II/III trials are excluded
Foreign eligibilityForeign organizations are not eligible, but foreign components of U.S. organizations may be allowed
NHLBI contactScientific contact should happen at least 12 weeks before submission

The quickest route decision is this: apply only when animal work is complete, the product can move through final readiness tasks, and the R33 clinical trial can start from objective R61 milestones.

8 NHLBI R61/R33 Eligibility Checks

Within 21 days, run 8 stop checks. If animal studies are still required, pause.

Stop checkStrong R61/R33 signalRed flag
Mission fitHeart, lung, blood, or sleep disorder is centralTopic sits outside NHLBI mission
Trial phasePhase 0 or Phase I, including bridging studyPhase II or later
Product typeTherapeutic or diagnostic intervention is namedBasic science only
R61 readinessFinal formulation, stability, shipping, IND, or Phase 0 tasks are leftDiscovery work remains
R33 executionTrial conduct milestones are measurableTrial plan is vague
BudgetR61 and R33 caps are respectedBudget is not phase-specific
Contact timingNHLBI contact occurs at least 12 weeks before submissionContact happens after draft completion
Route choiceR61/R33 is compared with R33-only, R34, Catalyze, R01, and institute routesPhased route is assumed

According to NIH, R61 budgets are limited to $250,000 in direct costs per year, and R33 budgets should not exceed $1,515,000 in direct costs per year. The combined maximum project period is 5 years.

5 Source Facts Applicants Should Know

According to PAR-25-026, the R61 phase can be up to 2 years, and the R33 phase can be up to 3 years.

For market context, early-phase trial funding is limited, so route fit matters before a team spends months on an application. Award data never replaces PAR-25-026 rules.

FactSource-backed read
NOFOPAR-25-026
ActivityR61/R33 phased award
Clinical trialRequired
R61 budgetUp to $250,000 direct costs per year
R33 budgetShould not exceed $1,515,000 direct costs per year

NHLBI also encourages early contact with Scientific/Research Contacts at least 12 weeks before submission.

According to NHLBI, early phase clinical trials should use the institute-specific trial routes listed in the clinical trial development continuum. According to NIH clinical trials policy, applicants must correctly identify whether human-subjects work meets the NIH clinical-trial definition before submission.

What NIH Doesn't Tell You

Within 21 days, answer 4 practical questions. First, readiness is the gate. If the intervention still needs animal work, the route is wrong. NHLBI points teams needing additional animal studies toward Catalyze grants or services.

Second, milestone quality matters as much as science. R61 completion must support transition into R33 trial execution. Weak milestones make the phased structure risky.

Third, "early phase" still needs operational maturity. Drug, device, biologic, diagnostic, supply, regulatory, recruitment, monitoring, and data systems all need a credible plan.

Fourth, the R61/R33 route is not a way to delay trial planning. The application has to address both phases from the start.

Grantsights analysis of award data and route evidence says applicants should apply only when animal work is complete, the product has a credible regulatory and supply path, and the R61 milestones can trigger a real R33 decision. If the team still needs animal studies, a drug-supply agreement, or a measurable trial-start milestone, this is a bad fit today.

6 Evidence Assets That Make This Proposal Stronger

Within 28 days, build 6 evidence assets. Asset 1 is the readiness memo. Explain why animal studies are complete and why only final-stage product or regulatory work remains.

Asset 2 is the HLBS mission-fit memo. Tie the therapeutic or diagnostic to NHLBI priorities and disease burden.

Asset 3 is the milestone table. Separate R61 start-up milestones from R33 trial execution milestones, with decision points and objective measures.

Asset 4 is the regulatory and supply plan. Name IND, IDE, manufacturing, shipping, stability, placebo, third-party support, and trial-start dependencies.

Asset 5 is the clinical-trial operations packet. Include protocol status, sites, recruitment, safety monitoring, statistics, data capture, and timeline.

Asset 6 is the route memo. Compare R61/R33 with R33-only, NHLBI R34, Catalyze, R01, device routes, and institute-specific trial routes.

5 Route Choices Before Drafting

Within 21 days, compare 5 routes.

RouteBetter first read when...Why
PAR-25-026 R61/R33Final start-up plus Phase 0/I trial execution are both neededPhased route fits
PAR-25-025 R33Trial can start without R61 start-up workR33-only may fit
NHLBI R34Pilot or planning work is neededSmaller planning route may fit
CatalyzeProduct still needs preclinical workNHLBI points animal-study needs there
Parent R01 clinical trial routeTrial is not product-development focusedGeneral route may fit

Warning: don't use R61/R33 because the trial is expensive. Use it because the project needs a milestone-driven handoff from final readiness to early trial execution.

6 Bad-Fit Signals

First, additional animal studies are needed. Second, the project is Phase II or later. Third, the intervention is not therapeutic or diagnostic.

Fourth, R61 milestones are subjective. Fifth, the R33 trial plan is thin. Sixth, NHLBI contact is late.

R61/R33 problems often show up in the milestone table. If milestones sound like "complete protocol" or "prepare documents" without objective criteria, reviewers won't trust the transition.

28-Day R61/R33 Readiness Plan

Days 1 through 4 should write the readiness memo, HLBS mission-fit memo, and route comparison. Days 5 through 9 should contact NHLBI and draft the milestone table.

Days 10 through 15 should finalize regulatory, product, shipping, supply, and third-party support plans. Days 16 through 21 should draft the clinical-trial operations packet and budget by phase. Days 22 through 28 should check PAR-25-026, NIH policy notices, trial forms, and source freshness.

Don't save NHLBI contact for the end. The page says early contact at least 12 weeks before submission is encouraged, and for this route that is practical advice.

5 Fit Signals Readers Can Use

Within 21 days, use these 5 signals before drafting. Signal 1 is HLBS mission fit. Signal 2 is final product readiness. Signal 3 is animal-study status. Signal 4 is objective R61-to-R33 milestone design. Signal 5 is route comparison against R33-only, R34, Catalyze, R01, and institute-specific trial routes.

For example, a company with complete animal work, a final formulation plan, an IND path, and a Phase I sleep-disorder trial may fit. A team that still needs animal toxicology should compare Catalyze or another preclinical route before drafting PAR-25-026.

5 Example Fit Tests For R61/R33 Teams

Within 21 days, test 5 hypothetical examples against PAR-25-026. A company with completed animal work, a final prototype, and a Phase I sleep-disorder trial plan may fit if the R61 phase covers final readiness and the R33 phase runs the trial. According to NIH, the mechanism is milestone-driven and uses an R61 start-up phase plus an R33 clinical-trial execution phase.

A biologics team that still needs animal toxicology should stop. NIH says submissions containing animal studies are not permitted for this NOFO, and NHLBI points teams needing additional animal work toward Catalyze routes.

A diagnostics team preparing a bridging study for a blood disorder can fit if it has a clear clinical use case, assay readiness, regulatory plan, and Phase I or Phase 0 design. It gets weaker if the proposal reads like exploratory biomarker discovery.

A heart-failure drug team with strong science but no drug supply agreement, placebo plan, IND path, or monitoring system is not ready. The route expects both start-up work and trial execution to be planned from the beginning.

A multi-site pediatric lung study may fit, but the facilities, performance sites, recruitment, and coordination details need to be plain. In some early trial outlines, the science is exciting but the operational plan makes the route look risky.

5 Final R61/R33 Review Questions

First, is the study a Phase 0 or Phase I clinical trial? Second, is all required animal work already done, since PAR-25-026 doesn't permit animal studies? Third, does the budget fit both caps, $250,000 direct costs a year for the R61 and $1,515,000 for the R33?

Fourth, are the R61 milestones objective enough to justify moving to the R33? Fifth, can the application be ready for February 3, 2027, the last due date under PAR-25-026? If all 5 answers are yes, contact NHLBI program staff before drafting.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 88 Assistance Listing records | Avg: $2.2M

REAL DATA
1

Washington University, the

MO

$9.5M
2

Weill Medical College of Cornell University

NY

$7.7M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-026 support?

It supports investigator-initiated Phase 0 and Phase I clinical trials, including bridging studies, for diagnostic and therapeutic interventions for heart, lung, blood, and sleep disorders.

Is a clinical trial required?

Yes. PAR-25-026 only accepts applications that propose clinical trials.

What is the R61 budget cap?

NIH says R61 phase budgets are limited to $250,000 in direct costs per year.

What is the R33 budget cap?

NIH says R33 phase budgets should not exceed $1,515,000 in direct costs per year.

Who should skip this NOFO?

Skip it when animal studies are still needed, the product is not ready for early human testing, or the trial is Phase II or later.

Last updated November 9, 2026. Corrected November 9, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.